Aimmune Therapeutics (AIMT) PT Raised to $44 at JMP Securities
February 3, 2020 4:40 AM
JMP Securities analyst Liisa Bayko raised the price target on Aimmune Therapeutics (NASDAQ: AIMT) to $44.00 (from $40.00) while maintaining a Market Outperform rating.
